Genetic studies indicate that three of the four polypeptides encoded within the virD operon of the Agrobacterium tumefaciens Ti plasmid are essential for virulence. In order to determine whether the fourth polypeptide, VirD3, has any role in virulence, complementation analysis was used. An A. tumefaciens strain, A348AD, which lacked the entire virD operon in the Ti plasmid pTiA6, was constructed. Plasmids containing defined regions of the virD operon were introduced into this strain, and virulence was tested by the strains' abilities to form tumors on Kalanchoe leaves, tomato stems, and potato tubers. As expected, deletion of the virD operon led to an avirulent phenotype. The virulence of this strain could be restored by providing virDI, virD2, and virD4 in trans. No requirement for virD3 in tumor formation was observed in these assays.
Agrobactenum tumefaciens is a phytopathogenic bacterium responsible for causing crown gall tumors on plants.
Tumor formation involves the transfer of a segment of a tumor-inducing (Ti) plasmid from the bacterium to the plant cell followed by the stable integration of the transferred DNA (T-DNA) into the plant nuclear genome (reviewed in references 16 and 28) . The T-DNA is flanked by a 24-bp imperfect direct-repeat sequence, the border sequence, at its termini. The DNA transfer process is catalyzed by the Ti plasmid virulence (vir) genes that are arranged in at least eight operons, virA through virH (3, 10, 13, 18) . Of these, virA and virG are the regulatory loci (20) and are members of the bacterial two-component regulatory systems. These genes are constitutively expressed in the bacterium and coordinately induce expression of all of the virulence genes when a bacterium encounters a susceptible host. Under these conditions, the Ti plasmid DNA is processed to form a single-stranded T-strand DNA that is believed to be an intermediate in the DNA transfer process (1, 19) .
The initial reaction for the T-strand DNA synthesis is catalyzed by the enzymes encoded within the virD locus (26) . DNA sequence analysis studies indicated that virD can potentially encode five polypeptides, VirDl to VirD5 (9, 15, 26) . Of these, the last open reading frame, VirD5, is not required for virulence. A sequence comparison of the proteins encoded within the virD operon of A. tumefaciens octopine Ti plasmid pTiA6, nopaline Ti plasmid pTiC58, and A. rhizogenes Ri plasmid pRiA4b show that three polypeptides, VirDl, VirD2, and VirD4, are most similar to their respective counterparts (90 to 95% homology). In contrast, the VirD3 polypeptides are much less conserved (31% homology [23] ). VirD2, in the presence of VirDl, catalyzes a site-and strand-specific nicking reaction at the T-DNA borders (9, 26) and becomes covalently attached to the 5' end of the nicked DNA (6, 8, 22, 24, 27) . This reaction is the first step for T-strand DNA synthesis. VirDl has been shown to possess a DNA-relaxing activity (4 The kanamycin resistance gene from pUC4K (21) was cloned as a PstI fragment downstream of the pTiA6 virD promoter region in plasmid pGP254.1 (14) to construct pAV20. A 3.2-kb XhoI fragment encompassing the virE operon was isolated as a BamHI fragment from pSW108 (25) and cloned into the SphI site of pAV20 to create pAV23. Before ligation, the restricted DNAs were treated with mung bean nuclease in order to generate compatible ends. Plasmid pAV23 was digested with EcoRI and was cloned into the EcoRI site of a tetracycline-resistant broad-host-range plasmid, pLAFR5 (11) to construct pAV25 (tetracycline and kanamycin resistant). Plasmid pAV25 was introduced into A. tumefaciens A348 by conjugal transfer with triparental mating (2) . In order to force homologous recombination, an incompatible, gentamycin-resistant plasmid, pPHlJI (7) , was introduced into A. tumefaciens A348/pAV25, and colonies resistant to both kanamycin (50 ,ug/ml) and gentamycin (40 ,ug/ml) were selected. These colonies were later tested for tetracycline (10 p,g/ml) sensitivity to ensure the loss of pAV25. A strain that is resistant to kanamycin and sensitive to tetracycline is expected to result from the replacement of the virD coding region with the kanamycin resistance gene and was designated A348AD. The deletion of the virD operon was confirmed by using Southern into the SmaI site of plasmid pAD1151 (Fig. 1) . Plasmid pADllSi contains the virDI through virD4 coding region under the control of the synthetic tac promoter (4) . In plasmid pAV32, the native virD promoter was placed immediately upstream of the coding sequences in order to reconstruct its native organization. In order to test the requirement of virD3 or virD4 in tumor formation, derivatives of pAV32 that can provide the other virD functions in trans were constructed. Plasmid pAV42 contains virDI through virD3 and was constructed by cloning a 2.8-kb EcoRI fragment of pAV32 into the broad-host-range vector pAD1085. Plasmid pAD1085 is a derivative of pTJS75 (17) with additional cloning sites.
Plasmid pAV59 contains the virDl, virD2, and virD4 coding regions. The virD promoter region is duplicated in this plasmid. One promoter element controls the expression of virD4, while the second one controls the expression of virDI and virD2. The different virD genes were cloned under separate promoters to simplify the cloning procedures. In order to construct pAV59, the plasmid pMP4 was first constructed by deleting the SmaI-SnaBI restriction fragment containing virDl through virD3 of pAV32. The virD4 gene under the control of its own promoter was isolated from plasmid pMP4 as a 3.8-kb BamHI fragment and was cloned into pAD1085 in order to construct pMP5. The virDl and virD2 coding sequence under the control of the native following Agrobacterium strains: A348, which contains the Ti plasmid pTiA6; A136, A348 cured of its Ti plasmid; A348AD, A348 with the virD operon deleted; AV58, A348AD plus pAV58; AV59, A348AD plus pAV59; AV42, A348AD plus pAV42. Plasmids pAV42, pAV59, and pAV58 contain virDl through virD3; virDl, virD2, and virD4; and virDl through virD4, respectively.
promoter was cloned as a 2.2-kb XbaI fragment from plasmid pAV52 into pMP5 in order to construct pAV59. Plasmid pAV52 was constructed by introducing a BglII restriction site within the intergenic region between virD2 and virD3 by using site-directed mutagenesis (12) and then deleting virD3 and -4 by digestion with BglII.
Plasmid pAV58, a positive control, contains virDl through virD4 with virDl and virD2 in one operon and virD3 and virD4 in a separate operon. In order to construct pAV58, virD3 and virD4 under the control of the virD promoter was cloned as a BamHI fragment from pMP1 into pAD1085 to create pMP3. pMP1 was constructed from pAV32 by deleting the 1.8-kb SmaI-NruI fragment encompassing virDl and virD2. The virDl and virD2 segment with the virD promoter was then introduced into pMP3 as a 2.2-kb XbaI fragment from plasmid pAV52 to construct pAV58.
All plasmids were conjugated intoA. tumefaciens A348AD by triparental mating (2) . Strain AV58 contains the wild-type construct pAV58, strain AV59 contains the plasmid pAV59, and strain AV42 contains the plasmid pAV42.
In order to test the requirement of virD3 and virD4 in tumorigenicity, the ability of the newly constructed strains to complement the virD deletion mutation was tested on several plants. In a Kalanchoe leaf assay, the virD-deleted A. tumefaciens strain A348AD was avirulent as expected (Fig. 2) 
